Vertex Pharma (VRTX) Misses Q1 EPS by 20c; Increases 2016 KALYDECO Revenue Guidance

Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $0.09, $0.20 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $398.1 million versus the consensus estimate of $439.36 million.

First quarter 2016 cystic fibrosis product revenues of $394 million; $223 million for ORKAMBI® (lumacaftor/ivacaftor) and $171 million for KALYDECO® (ivacaftor)-

-Provides 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion; increases 2016 guidance for KALYDECO product revenues to $685 to $705 million-

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
• BMO Capital Reiterates Outperform Rating on Vertex (VRTX)